内科

目的探讨阿立哌唑治疗女性精神分裂症患者的临床疗效及安全性。方法将64例女性精神分裂症患者随机分为两组，每组各32例，研究组给予阿立哌唑治疗，对照组给予利培酮治疗，疗程均为8周。采用阳性与阴性症状量表（PANSS）及症状量表（TESS）于治疗前及治疗2 、4、8周末各评定1次。结果两组治疗后PANSS评分较治疗前均显著下降，差异有统计学意义（P＜0.01）。治疗后两组PANSS评分差异无统计学意义（P＞0.05），但研究组的锥体外系不良反应、体重增加及月经紊乱等均较对照组少且轻。结论阿立哌唑及利培酮对女性精神分裂症均有较好的疗效，但阿立哌唑不良反应更轻，依从性好。

ObjectiveTo investigate the clinical efficacy and safety of aripiprazole in treatment of female patients with schizophrenia.Methods64 female patients with schizophrenia were randomly divided into two groups,each group with 32 patients.The study group was given aripiprazole treatment,while the control group was given risperidone. Both groups were treated for 8 weeks.Positive and negative syndrome scale (PANSS) and symptom scale (TESS) were used to assess the efficacy before treatment and at the time of 2nd,4th,and 8th week,respectively.ResultsPANSS scores in both groups after treatment were significantly decreased compared with those before the treatment (P＜0.01),but no significantly difference was found after treatment between two groups.The study group showed less extrapyramidal side effects,weight gain and menstrual than the control group.ConclusionsBoth aripiprazole and risperidone can improve the efficacy of schizophrenic in female patients,but aripiprazole has fewer side effects and better compliance.

ref